Shunji Matsuki

The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co

O. Nemoto, M. Furue, Hidemi Nakagawa et al. · British Journal of Dermatology · 2015 · 186 citations · Full text

Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers

Daiki Mori, Yushi Kashihara, Takashi Yoshikado et al. · Drug Metabolism and Pharmacokinetics · 2018 · 65 citations

Plasma Concentrations, Nutrition, Physiology +3

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides

Kei Sakamoto, Shunji Matsuki, Kyoko Matsuguma et al. · The Journal of Clinical Pharmacology · 2017 · 59 citations

Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP

Yushi Kashihara, Ichiro Ieiri, Takashi Yoshikado et al. · Journal of Pharmaceutical Sciences · 2017 · 50 citations

Molecular Pharmacology, Small-dosing Clinical Study, Pharmacology +5

Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study

Fuminori Ohba, Shunji Matsuki, Shuhei Imayama et al. · Journal of Dermatological Treatment · 2016 · 41 citations